1887

Journal of Medical Microbiology logo

Volume 57, Issue 11

Human infections with verocytotoxin-producing O157 – 10 years of O157 serodiagnosis Free

Abstract

From 1997 to 2007, the Laboratory of Enteric Pathogens (LEP), Health Protection Agency, UK, received sera from 2148 patients for testing for antibodies to the LPS of verocytotoxin-producing (VTEC) O157. A total of 676 (31.5 %) sera had antibodies binding the LPS of O157 and the majority of patients were below the age of 10 years, a trend observed for both males and females. Antibody-positive patients had haemolytic uraemic syndrome (HUS) in 79.3 % of cases and most of these presented with the atypical (D−) form of HUS. Nine patients were shown to have antibodies to the LPS of belonging to serogroups O26 (4), O103 (2), O111 (1) and O145 (2) and one patient had antibodies to the somatic antigens of both O26 and O103. The serodiagnosis of infections with O157 and other VTEC continues to be an important adjunct to bacteriology. Where clinicians suspect the involvement of a VTEC in disease, patients' sera should be submitted to the LEP for analysis without delay.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): HUS, haemolytic uraemic syndrome , LEP, Laboratory of Enteric Pathogens and VTEC, verocytotoxin-producing Escherichia coli
SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.2008/003632-0
2008-11-01
2024-04-16
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/11/1389.html?itemId=/content/journal/jmm/10.1099/jmm.0.2008/003632-0&mimeType=html&fmt=ahah

References

  1. Amor K., Heinrichs D. E., Frirdich E., Ziebell K., Johnson R. P., Whitfield C. 2000; Distribution of core oligosaccharide types in lipopolysaccharides from Escherichia coli . Infect Immun 68:1116–1124 [CrossRef]
     [Google Scholar]
  2. Bitzan M., Ludwig K., Klemt M., König H., Büren J., Müller-Wiefel D. E. 1993; The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study. Epidemiol Infect 110:183–196 [CrossRef]
     [Google Scholar]
  3. Chart H. 2000; Clinical significance of Verocytotoxin-producing Escherichia coli serotype O157. World J Microbiol Biotechnol 16:719–724 [CrossRef]
     [Google Scholar]
  4. Chart H. 2003; The pathogenicity of strains of Salmonella paratyphi B and Salmonella java . J Appl Microbiol 94:340–348 [CrossRef]
     [Google Scholar]
  5. Chart H., Jenkins C. 1998; Salivary antibodies to lipopolysaccharide antigens of Escherichia coli serotype O157. Lancet 352:371
     [Google Scholar]
  6. Chart H., Jenkins C. 1999; Serodiagnosis of infections caused by verocytotoxin-producing Escherichia coli . J Appl Microbiol 86:731–740 [CrossRef]
     [Google Scholar]
  7. Chart H., Scotland S. M., Rowe B. 1989; Serum antibodies to Escherichia coli serotype O157 : H7 in patients with hemolytic uremic syndrome. J Clin Microbiol 27:285–290
     [Google Scholar]
  8. Chart H., Cheasty T., Cope D., Gross R. J., Rowe B. 1991; The serological relationship between Yersinia enterocolitica O9 and Escherichia coli O157 using sera from patients with yersiniosis and haemolytic uraemic syndrome. Epidemiol Infect 107:349–356 [CrossRef]
     [Google Scholar]
  9. Chart H., Okubadejo O. A., Rowe B. 1992; The serological relationship between Escherichia coli O157 and Yersinia enterocolitica O9 using sera from patients with brucellosis. Epidemiol Infect 108:77–85 [CrossRef]
     [Google Scholar]
  10. Chart H., Cheasty T., Giorgio T., Rowe B. 1993; Antigenic cross-reactions between Escherichia coli O157, Vibrio cholerae O1 Inaba and group N Salmonella . Serodiag Immunother Inf Dis 5:81–84 [CrossRef]
     [Google Scholar]
  11. Chart H., Cheasty T., Willshaw G. A. 2002a; Production of serum antibodies that recognise epitopes located on the R3 region of Escherichia coli core lipopolysaccharides in patients infected with strains of enterohaemorrhagic E. coli . J Med Microbiol 51:1050–1054
     [Google Scholar]
  12. Chart H., Perry N. T., Cheasty T., Wright P. A. 2002b; The kinetics of antibody production to antigens of Escherichia coli O157 in a pregnant woman with haemolytic uraemic syndrome. J Med Microbiol 51:522–525
     [Google Scholar]
  13. Chart H., Perry N. T., Willshaw G. A., Cheasty T. 2003; Analysis of saliva for antibodies to the LPS of Escherichia coli O157 in patients with serum antibodies to E. coli O157 LPS. J Med Microbiol 52:569–572 [CrossRef]
     [Google Scholar]
  14. Chart H., Perry N. T., Jenkins C. 2004; The expression of an R3 lipopolysaccharide-core by pathotypes of Escherichia coli . J Appl Microbiol 96:982–986 [CrossRef]
     [Google Scholar]
  15. Dalwai F., Chart H. 2003; Human antibody responses to R3-core epitopes on the lipopolysaccharide of Escherichia coli O157. Lett Appl Microbiol 37:429–432 [CrossRef]
     [Google Scholar]
  16. Evans J., Chalmers R. M., Chart H., Salmon R. L., Kench S. M., Coleman T. J., Meadows D., Morgan-Capner P., Softley P. other authors 2000; Evidence of persisting serum antibodies to Escherichia coli O157 lipopolysaccharide and Verocytotoxin in members of rural communities in England. Eur J Epidemiol 16:885–889 [CrossRef]
     [Google Scholar]
  17. Fitzpatrick M. 1999; Haemolytic uraemic syndrome and E. coli O157 – prevention rests with sound public health measures. BMJ 318:684–685 [CrossRef]
     [Google Scholar]
  18. Havelaar A. H., Van Duynhoven Y. T., Nauta M. J., Bouwknegt M., Heuvelink A. E., De Wit G. A., Nieuwenhuizen M. G., van de Kar N. C. 2004; Disease burden in The Netherlands due to infections with Shiga toxin-producing Escherichia coli O157. Epidemiol Infect 132:467–484 [CrossRef]
     [Google Scholar]
  19. Heinrichs D. E., Yethon J. A., Whitfield C. 1998; Molecular basis for structural diversity in the core regions of the lipopolysaccharides of Escherichia coli and Salmonella enterica . Mol Microbiol 30:221–232 [CrossRef]
     [Google Scholar]
  20. Jenkins C., Chart H. 1999a; Antibodies to lipopolysaccharides of Escherichia coli serogroups O5 and O165 in healthy adults. Lancet 354:649
     [Google Scholar]
  21. Jenkins C., Chart H. 1999b; Serodiagnosis of infection with verocytotoxin-producing Escherichia coli serogroups. J Appl Microbiol 86:569–575 [CrossRef]
     [Google Scholar]
  22. Jenkins C., Evans J., Chart H., Willshaw G. A., Frankel G. 2008; Escherichia coli serogroup O26 – a new look at an old adversary. J Appl Microbiol 104:14–25
     [Google Scholar]
  23. Karch H., Tarr P. I., Bielaszewska M. 2005; Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 295:405–418 [CrossRef]
     [Google Scholar]
  24. Karmali M. A., Petric M., Lim C., Fleming P. C., Arbus G. S., Lior H. 1985; The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli . J Infect Dis 151:775–782 [CrossRef]
     [Google Scholar]
  25. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685 [CrossRef]
     [Google Scholar]
  26. Levin M., Barratt T. M. 1984; Haemolytic uraemic syndrome. Arch Dis Child 59:397–400 [CrossRef]
     [Google Scholar]
  27. Lynn R. M., O'Brien S. J., Taylor C. M., Adak G. K., Chart H., Cheasty T., Coia J. E., Gillespie I. A., Locking M. E. other authors 2005; Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 11:590–596 [CrossRef]
     [Google Scholar]
  28. Mead P. S., Griffin P. M. 1998; Escherichia coli serotype O157 : H7. Lancet 352:1207–1212 [CrossRef]
     [Google Scholar]
  29. Robins-Browne R. M. 1987; Traditional enteropathogenic Escherichia coli of infantile diarrhea. Rev Infect Dis 9:28–53 [CrossRef]
     [Google Scholar]
  30. Rowe P. C., Orrbine E., Lior H., Wells G. A., McLaine P. N. 1993; A prospective study of exposure to verotoxin-producing Escherichia coli among Canadian children with haemolytic uraemic syndrome. Epidemiol Infect 110:1–7 [CrossRef]
     [Google Scholar]
  31. Scotland S. M., Willshaw G. A., Smith H. R., Rowe B. 1990; Properties of strains of Escherichia coli O26 : H11 in relation to their enteropathogenic or enterohemorrhagic classification. J Infect Dis 162:1069–1074 [CrossRef]
     [Google Scholar]
  32. Tarr P. I., Gordon C. A., Chandler W. L. 2005; Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073–1086
     [Google Scholar]
  33. Thomas A., Chart H., Cheasty T., Smith H. R., Frost J. A., Rowe B. 1993; Vero cytotoxin-producing Escherichia coli , particularly serogroup O 157, associated with human infections in the United Kingdom: 1989–91. Epidemiol Infect 110:591–600 [CrossRef]
     [Google Scholar]
  34. Thomas A., Cheasty T., Frost J. A., Chart H., Smith H. R., Rowe B. 1996; Vero cytotoxin-producing Escherichia coli , particularly serogroup O157, associated with human infections in the United Kingdom: 1992–4. Epidemiol Infect 117:1–10 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.2008/003632-0
Loading
Human infections with verocytotoxin-producing Escherichia coli O157 – 10 years of E. coli O157 serodiagnosis
J. Med. Microbiol. 57, 1389 (2008); https://doi.org/10.1099/jmm.0.2008/003632-0
/content/journal/jmm/10.1099/jmm.0.2008/003632-0
/content/journal/jmm/10.1099/jmm.0.2008/003632-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error